×
About 21,938 results

Natural History and Development of Spondyloarthritis
https://clinicaltrials.gov/ct2/show/NCT01422694

Jan 31st, 2023 - The purpose of this protocol is to study the natural history of spondyloarthritis (SpA) in children and adults. Spondyloarthritis encompasses a spectrum of immune-mediated inflammatory diseases that exhibit overlapping features, but differ from other types of inflammatory arthritis in genetic predisposition, pathogenesis, and outcome. Ankylosing spondylitis (AS), the most common form of SpA, fr...

Phase II Study to Assess Safety and Efficacy of SL-1002 for Osteoarthritic Knee Pain
https://clinicaltrials.gov/ct2/show/NCT05470608

Feb 3rd, 2023 - This is a multicenter, randomized, double-blind, placebo-controlled, single ascending dose escalation study to assess the safety and efficacy of single treatment exposure of an injectable formulation of SL-1002 for the treatment of knee pain associated with osteoarthritis. Phase A of the study will enroll 3 cohorts of 8 patients per cohort, for a total of 24 patients. Patients will be randomize...

Interest of an Adapted Physical Activity (APA) Program Among Patients With Juvenile Idiopathic Arthritis: a Feasibility and Efficacy Preliminary Study
https://clinicaltrials.gov/ct2/show/NCT05572424

Feb 3rd, 2023 - The Juvenile Idiopathic Arthritis (JIA) affects joints mobility and leads pain, impacting the practice of physical activities. Adapted Physical Activities are rehabilitation methods increasingly used, but additional studies are needed to define the nature of the physical activity for patients with JIA. The ATHLETIQUE project aims to evaluate the impact of a program integrating APA sessions toge...

Evaluating Intra-articular Injection of Axolotl Ambient Compared to Saline in Subjects With Ankle Osteoarthritis
https://clinicaltrials.gov/ct2/show/NCT05092646

Feb 3rd, 2023 - This pilot study is a double-blind multi-center, prospective, randomized, placebo-controlled trial. Upon randomization, patients will receive 1 intraarticular injection of the investigational product or control fluid. Follow-up will be conducted at 4 weeks, 3 and 6 months, with 6 months serving as the primary endpoint. The primary outcomes will consist of patient reported outcomes of pain and f...

Optimization of Total Knee Arthroplasty Using Robotic Systems
https://clinicaltrials.gov/ct2/show/NCT05712291

Feb 3rd, 2023 - Relevance: Robotic orthopedic surgery has been around for over twenty years and is becoming more relevant every day. Modern systems consist of a robotic arm, robotic cutting tools and robotic milling systems with a variety of navigation systems with using active, semi-automatic or passive control systems. In the analysis of clinical studies, it can be concluded that these robotic systems reduce...

Spinal Anaesthesia vs. General Anaesthesia for THA, TKA and UKA
https://clinicaltrials.gov/ct2/show/NCT05706844

Feb 3rd, 2023 - The goal of this randomized clinical trial is to investigate the postoperative recovery following hip and knee arthroplasty procedures depending on the use of either spinal anaesthesia (SA) or general anaesthesia (GA). The main questions are: Are more patients able to be safely mobilized within 6 hours postoperatively when using GA compared to SA? Does postoperative pain, nausea and vomiting, d...

rTMS for Relieving Chronic OA Pain
https://clinicaltrials.gov/ct2/show/NCT05097729

Feb 3rd, 2023 - Osteoarthritis (OA) pain is one of the most prevalent causes of chronic pain worldwide. Symptoms can last from months to a lifetime, severely impacting patients' quality of life. New strategies - including non-invasive brain stimulation techniques - have shown promise for sustained pain relief, yet evidence on their reliability and efficacy is limited. Apkarian et. al have previously shown that...

Altering Bone Microarchitecture and Mechanics by Off-label Pharmaceutical Intervention Following an Acute Knee Injury
https://clinicaltrials.gov/ct2/show/NCT05204836

Feb 3rd, 2023 - After being informed about the study and potential risks and all participants giving written informed consent, this project will establish a cohort of young men and women who within six weeks have sustained an acute rupture of the ACL. The cohort is randomized into a control and treatment group, where the treatment group receives a zoledronic acid injection at baseline. The cohort will be follo...

Adapting REhabilitation Delivery for Maximum Impact at Home
https://clinicaltrials.gov/ct2/show/NCT05164575

Feb 3rd, 2023 - ReDI@Home is a randomized feasibility trial that will evaluate implementation of home-based interventions to assist persons with moderate to advanced hip or knee osteoarthritis (OA) living in rural environments with self-management. Although others have used similar web-based interventions for urban patients living with inflammatory arthritis, our selected group of rural residents living with O...

Cervical Stabilization Exercises in Patients With Spondyloarthritis
https://clinicaltrials.gov/ct2/show/NCT04483648

Feb 3rd, 2023 - The position sense and kinesthesia are defined as proprioception. In other words, proprioception allows being aware of positions of the body parts in the space. Muscles, tendons, joint capsules are source of proprioception. Possible damage to these structures due to inflammation may cause diminished proprioception sense. Decreased proprioception was shown for cervical region in axial spondyloar...

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis
https://clinicaltrials.gov/ct2/show/NCT03928704

Feb 3rd, 2023 - The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active nonradiographic axial spondyloarthritis (nr-axSpA).

Digital Osteoarthritis Care
https://clinicaltrials.gov/ct2/show/NCT04767854

Feb 3rd, 2023 - The study is a two-armed non-inferiority randomized controlled trial (RCT) situated in the primary care setting in Norway. Participants diagnosed with hip and/or knee OA will be randomized to either exercise therapy via app or usual care. Patients aged 18 years and older presenting with activity-related hip and/or knee pain/complaints and clinical signs and symptoms corresponding to hip and/or ...

Routine Application of Ostenil® in Patients With Gonarthrosis
https://clinicaltrials.gov/ct2/show/NCT03734315

Feb 3rd, 2023 - PMCF study to observe the routine application of Ostenil® in the treatment of pain and restricted mobility in degenerative and traumatic changes of the knee joint.

Routine Application of Ostenil® Mini in Patients With Rhizarthrosis
https://clinicaltrials.gov/ct2/show/NCT03879434

Feb 3rd, 2023 - PMCF study to observe the routine application of Ostenil® Mini in the treatment of pain and restricted mobility in degenerative and traumatic changes of the CMC joint.

Efficacy and Safety of Ostenil® Plus in the Treatment of Coxarthrosis
https://clinicaltrials.gov/ct2/show/NCT03809962

Feb 3rd, 2023 - PMCF study to observe the Routine application of Ostenil® Plus in the Treatment of pain and restricted mobility in degenerative and traumatic changes of the Hip Joint.

Novel PET Radioligands as Inflammatory Biomarkers in Rheumatoid Arthritis and Myositis
https://clinicaltrials.gov/ct2/show/NCT03912428

Feb 3rd, 2023 - I. Objective 18-kDa translocator protein (TSPO) and cyclooxygenase-2 (COX-2) are both implicated in the pathophysiology of various inflammatory disorders, suggesting that both may serve as potential biomarkers of inflammation in brain as well as periphery. Our laboratory recently developed two new radioligands: [11C]ER176 to image TSPO and [11C]MC1 to image COX-2. Using wholebody imaging, this ...

S-Asenosyl-L-Methionine vs Placebo for Osteoarthritis of the Hands
https://clinicaltrials.gov/ct2/show/NCT05363020

Feb 2nd, 2023 - At week 0, all patients giving written informed consent and meeting eligibility requirements will be randomized in a double-blind manner (participant and investigator) in a 1:1 ratio to SAMe (400mg orally, twice daily) or placebo (400mg, twice daily) for 8 weeks. Followed by a one week wash out period followed by another 8 weeks of SAMe (400mg, twice daily) or placebo (400mg, twice daily) for 8...

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral Doses of TCK-276 in Patients With Rheumatoid Arthritis
https://clinicaltrials.gov/ct2/show/NCT05437419

Feb 2nd, 2023 - This is a Phase 1, multi-center, double-blind, randomized, placebo-controlled, multiple ascending dose (MAD) study. The study will consist of a Screening Visit (Days -1 to Day 10), Treatment duration (up to 11 days) and a Follow-up/end of treatment (EOT) visit. This MAD study will consist of 4 cohorts of 8 patients (6 active treatment and 2 matching placebo, or a 3:1 ratio), each receiving an o...

A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or Psoriasis
https://clinicaltrials.gov/ct2/show/NCT05252533

Feb 2nd, 2023 - jPsA is a complex, chronic, progressive, debilitating musculoskeletal disease with significant remaining medical need. There is a need for medications which have a similar efficacy profile and a well-characterized safety profile relative to currently available tumor necrosis factor alpha (TNF alpha) inhibitors for jPsA participants with active disease. STELARA (ustekinumab) is a fully human imm...

A Long-term Extension Study of Ustekinumab in Pediatric Participants
https://clinicaltrials.gov/ct2/show/NCT05092269

Feb 2nd, 2023 - The purpose of this study is to collect long-term safety data of subcutaneous (SC) ustekinumab